PHT selects Windows 8.1 tablets to run SitePad System for clinical trials
PHT, a provider of technologies used to collect patient-driven eData for clinical research, has selected Dell Venue 11 Pro tablets featuring Windows 8.1 to run its SitePad System. The SitePad System replaces traditional paper data collection methods in clinical research with electronic methods, providing better-quality data, real-time access to that data and, ultimately, faster time to data analysis for pharmaceutical trial sponsors. The SitePad System is used in clinical trials to collect clinician- and patient-reported outcomes for supporting label claims of new therapies.
PHT selected the Dell Venue 11 Pro because of its high-resolution touch screen that supports greater ease of use for both clinicians and patients, and its multiple modes of data communications including Wi-Fi, Ethernet and an embedded 4G card.
PHT chose the Windows 8.1 tablets because of the flexibility and security aspects of Microsoft technology and because the solution allows PHT to increase the quality of real-time site-based data capture for trial participants and clinicians. It also allows PHT to run custom software that helps decrease clinical trial costs for sponsors by reducing time spent downstream resolving missing and inconsistent data. The end-user experience helps provide additional convenience and comfort, enabling rapid entry of electronic source clinical data.
Sheila Rocchio, PHT vice president of marketing and product management, said, “Paper is no longer the gold standard, and clinical trial sponsors are rapidly abandoning paper methods for collecting critical information about how patients feel and function in addition to key clinician observations and assessments. In one recent trial, the SitePad System saved the sponsor more than 30% over the cost of paper.”
PHT has purchased more than 2,000 Dell Venue 11 Pros, which will be deployed at clinical trial sites around the globe. Each SitePad is configured for a specific study protocol and used by clinicians and patients participating in the trial to collect study-specific assessments. Data collected on the SitePad device are sent to StudyWorks, the PHT online portal that provides real-time information about compliance as well as key measures used for study operations and patient safety monitoring. Each tablet is preconfigured with study-specific schedules, assessments and questionnaires. Patient and clinician compliance with SitePad on average exceeds 98.5%.